Home » Stocks » FATE

Fate Therapeutics, Inc. (FATE)

Stock Price: $89.72 USD 3.45 (4.00%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $89.70 -0.02 (-0.02%) Feb 26, 7:08 PM
Market Cap 8.41B
Revenue (ttm) 31.43M
Net Income (ttm) -173.39M
Shares Out 82.39M
EPS (ttm) -2.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $89.72
Previous Close $86.27
Change ($) 3.45
Change (%) 4.00%
Day's Open 88.67
Day's Range 84.02 - 93.29
Day's Volume 1,195,351
52-Week Range 16.75 - 121.16

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 2 days ago

FATE reports a wider Q4 loss on increased R&D expenses.

Other stocks mentioned: BMY, GILD, JNJ
Benzinga - 3 days ago

Shares of Fate Therapeutics (NASDAQ:FATE) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 64.86% over the past year to ($0.61...

GlobeNewsWire - 3 days ago

Positive Interim Data Reported from FT516 Phase 1 Study in Relapsed / Refractory BCL; Objective Responses, including Two Complete Responses, Achieved in 3 of 4 Patients in Dose Cohorts 2 and 3

GlobeNewsWire - 5 days ago

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the developm...

GlobeNewsWire - 1 week ago

SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the developm...

Forbes - 2 weeks ago

The stock price of Fate Therapeutics has seen a solid 16% rise over the last five trading days, while it's up 13% over the last ten trading days, and we believe the rally may continue in the n...

The Motley Fool - 4 weeks ago

Time will always be on the investor's side.

Other stocks mentioned: CORT, CRSP, JNCE, LXRX
The Motley Fool - 4 weeks ago

These two companies are at the forefront of innovation during our golden age of biotech.

Other stocks mentioned: BNTX
Forbes - 1 month ago

After a stellar 5x rise since the March 23 levels of last year, at the current price of around $114 per share we believe Fate Therapeutics stock, a biopharmaceuticals company focused on oncolo...

Benzinga - 1 month ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider bu...

Other stocks mentioned: CAG, ALDX, DMTK, GBIO, MRSN, ORI, REVG, RILY, SPT, YORW
Kiplinger - 1 month ago

If you desire growth, then your sights should be set on small-cap stocks. These 11 have attracted the gaze of dozens of Wall Street's best minds.

Other stocks mentioned: BJ, GLNG, GTLS, HCAT, IIVI, LPSN, NVRO, PDCE, PZZA, QTS
GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the developm...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Fate Therapeutics (FATE) stock based on the movements in the options market lately.

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the developm...

The Motley Fool - 1 month ago

Clinical trial readouts this year could cause these closely watched biotech stocks to explode overnight.

Other stocks mentioned: BBIO, EDIT
GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the developm...

Zacks Investment Research - 1 month ago

Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.

Other stocks mentioned: MRNA, MRSN, NTLA, RARE
Zacks Investment Research - 1 month ago

FATE's recent positive pipeline updates have led to a significant upsurge in the stock price.

The Motley Fool - 2 months ago

The biotech's natural killer cell therapies have real potential.

Zacks Investment Research - 2 months ago

The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.

Other stocks mentioned: EDIT, FOLD, RARE, XLRN
Zacks Investment Research - 2 months ago

Fate Therapeutics (FATE) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Zacks Investment Research - 2 months ago

Fate (FATE) stock up on positive data from its early-stage study on its NK cell product candidate at ASH.

Pulse2 - 2 months ago

The stock price of Fate Therapeutics Inc (NASDAQ: FATE) has increased by 37.8% (from $60.79 on December 6 to $83.77 on December 7). This is why.

The Motley Fool - 2 months ago

The biotech reported great news on Friday and Saturday for two of its cancer immunotherapy candidates.

GlobeNewsWire - 2 months ago

Off-the-Shelf, iPSC-derived CAR NK Cell Product Candidate Drives Partial Response at First Dose Level of 30 Million Cells

Zacks Investment Research - 2 months ago

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 2 months ago

3 of 4 Patients Evaluable for Efficacy in Dose Escalation Cohorts 2 and 3 Show Objective Response, with 2 Patients Achieving Complete Response

GlobeNewsWire - 2 months ago

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherap...

GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherap...

Seeking Alpha - 3 months ago

Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -24.14% and -25.76%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for t...

GlobeNewsWire - 3 months ago

First Patients Treated with Dual-Antigen Targeting Regimen of FT596 in Combination with Rituximab for B-cell Lymphoma

GlobeNewsWire - 4 months ago

SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunothera...

GlobeNewsWire - 5 months ago

SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunothe...

GlobeNewsWire - 6 months ago

SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunother...

Seeking Alpha - 6 months ago

Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -75.00% and -73.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the st...

GlobeNewsWire - 6 months ago

Partial Response Reported with FT596 Monotherapy at First Dose Level in Refractory DLBCL Patient

GlobeNewsWire - 6 months ago

SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunother...

GlobeNewsWire - 6 months ago

SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunother...

Zacks Investment Research - 6 months ago

Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 7 months ago

Probably, but it depends on whether the company can deliver on its cost-cutting potential.

The Motley Fool - 7 months ago

Two decades is a long time, but these up-and-coming biopharma companies could earn significantly larger valuations in that span.

Other stocks mentioned: DRNA
GlobeNewsWire - 7 months ago

License Covers First-in-class Alloimmune Defense Receptors Designed to Protect Allogeneic Cells from Rejection in Immunocompetent Recipients

Zacks Investment Research - 7 months ago

Fate (FATE) obtains FDA clearance for its IND application for FT819, targeting CD19+ malignancies.

Benzinga - 8 months ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from.

Other stocks mentioned: CI, UBER, AAP, AES, AXS, BMY, CNNE, COO, EPD, FOX, PK, TFC, VFC
GlobeNewsWire - 8 months ago

SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the develo...

The Motley Fool - 8 months ago

The cell therapy developer announced the next step for an important pipeline asset.

The Motley Fool - 8 months ago

The company has some additional capital to support the development of its pipeline.

GlobeNewsWire - 8 months ago

SAN DIEGO, June 09, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the develo...

About FATE

Fate Therapeutics, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of adv... [Read more...]

Industry
Biotechnology
IPO Date
Oct 1, 2013
CEO
William Rastetter
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
FATE
Full Company Profile

Financial Performance

In 2020, FATE's revenue was $31.43 million, an increase of 194.33% compared to the previous year's $10.68 million. Losses were -$173.39 million, 76.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to 16 analysts, the average rating for FATE stock is "Buy." The 12-month stock price forecast is 103.00, which is an increase of 14.80% from the latest price.

Price Target
$103.00
(14.80% upside)
Analyst Consensus: Buy